This Week in Sleep Medicine: February 26, 2019
While You Were Sleeping: What Sleep Technologists Need to Know This Week
Your media watchdog for headlines and trends
relevant to sleep technology and patient education.
From the article: “RespireRx Pharmaceuticals Inc, which is researching and developing cannabinoids for the treatment of sleep-related breathing disorders, has entered into a non-binding memorandum of understanding and exclusivity agreement with Impression Healthcare Ltd. The non-binding memo is for the purpose of negotiating terms by which the parties would enter in an arrangement, such as a license, joint venture, or partner agreement, so as to commercialize dronabinol for the treatment of obstructive sleep apnea (OSA) in Australia, New Zealand, and Southeast Asia.”
Takeaway: If you participated in the Journal Club last year focused on dronabinol, you saw this coming down the pipeline.
HEALTH LITERACY WATCH
PUBLIC SAFETY WATCH
Employee Fatigue Needs to be Addressed Immediately
February 22, 2019
From the article: “According to National Safety Council research, 90 percent of America’s employers have been negatively impacted by tired employees. Forty-three percent of employees admit they may be too tired to function safely at work. With fatigue becoming an increasingly common workplace hazard, the National Safety Council is calling on all employers to implement comprehensive programs—known as fatigue risk management systems—that can help prevent the roughly 13 percent of workplace injuries attributable to sleep problems.”
Sleep and sleep disorders in Franz Kafka's narrative works
December 31, 2018
From the abstract: “We read Kafka's complete literary works looking for references to sleep and sleep disorders, excluding insomnia.”